J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx (RARE) on January 4. The company’s shares closed yesterday at $45.40, close to its 52-week low of $37.44.
According to TipRanks.com, Kasimov is a 1-star analyst with an average return of -0.4% and a 38.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Ultragenyx is a Moderate Buy with an average price target of $70.60, which is a 55.5% upside from current levels. In a report issued on January 6, Cowen & Co. also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $87.31 million. In comparison, last year the company had a GAAP net loss of $81.73 million.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in October 2018, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
